Summit Therapeutics Inc. (SMMT) Stock
Key stats
- Market cap
- $13.31B
- Price / Earnings ratio
- -17.1x
- EPS (TTM)
- -$1.06
- Volume
- Loading
- 52-week high
- $29.23
- 52-week low
- $12.07
Source: third-party data provider, as of November 13, 2026
Compare with SMMT
Recent news

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
SMMT

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
SMMT

Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
SMMT

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
SMMT
News tone: automated (AI) classification of the article's content, not a price prediction.
Technical indicators
- RSI 14
- 52.51
- MACD 12/26/9
- 0.19
- EMA 9 of MACD
- -0.03
- MACD histogram
- 0.22
- SMA 50
- $16.46
- Price above SMA 50
- EMA 50
- $15.97
- Price above EMA 50
- SMA 200
- $16.16
- Price above SMA 200
- EMA 200
- $16.42
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst ratings
Analyst consensus: Hold
Based on 5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
Financials
Performance
Debt & Balance Sheet
Revenue to Profit
2025Earnings
The market is expecting earnings per share of -$0.33 for this quarter. The company has not yet shared when it is announcing earnings.
Source: third-party data provider
Latest news

Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
Biotech Beats SPY And QQQ In Market Rout — Now Hims Earnings And Summit’s FDA Test Take Center Stage ‘
SMMT

Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
Buy the Dip: 4 Stocks the Market Marked Down Too Far Ahead of Big Catalysts
SMMT

Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
Stocktwits Pharma Pulse: Big Pharma Earnings, Cancer Updates And 2 FDA Deadlines — The Week’s Biotech Watchlist
SMMT

Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
Ivonescimab Plus Chemotherapy Demonstrates Overall Survival Superiority Compared to Durvalumab Plus Chemotherapy in First-Line Treatment of Patients with Advanced Biliary Tract Cancer in HARMONi-GI1 Study Conducted by Akeso in China
SMMT

Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
Summit Therapeutics and Lunit Announce Agreement to Apply AI-powered SCOPE IO Platform for Tumor Microenvironment Analysis in Immuno-Oncology Development
SMMT

Summit Expands Ivonescimab Development Into Biliary Tract Cancer
Summit Expands Ivonescimab Development Into Biliary Tract Cancer
SMMT

Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
Ivonescimab Data Sets across Multiple Tumor Types to Be Featured at ESMO 2026
SMMT

Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
Can Expanding Ivonescimab Development Unlock SMMT's Growth Potential?
SMMT

Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
Summit Therapeutics and ECOG-ACRIN Cancer Research Group Enter into Phase II / III Clinical Trial Collaboration to Evaluate Ivonescimab in First-Line Biliary Tract Cancer
SMMT

Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
Summit Therapeutics Announces Opening of Global Phase II Study of Ivonescimab-Based Regimens in Advanced Clear Cell Renal Cell Carcinoma
SMMT
News tone: automated (AI) classification of the article's content, not a price prediction.
About Summit Therapeutics Inc.
Summit Therapeutics Inc is a biopharmaceutical company that focuses on the discovery, development, and commercialization of novel antibiotics for serious infectious diseases. Its CDI (Clostridiodes difficile infection) product candidate is ridinilazole, an orally administered small molecule antibiotic. It has two geographical segments: the United States and the United Kingdom.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Robert W. Duggan | Co-CEO & Executive Chairman | 1944 |
| Dr. Mahkam Zanganeh D.D.S., M.B.A. | Co-CEO, President & Director | 1970 |
| Prof. Kay Elizabeth Davies DBE, FRS CBE | Co-Founder, Chairman of Scientific Advisory Board and Scientific Advisor | 1951 |
| Mr. Manmeet Singh Soni CPA | COO, CFO & Director | 1978 |
| Mr. Bhaskar Anand | Chief Accounting Officer & Head of Finance | 1978 |
| Mr. Nathan LiaBraaten | Senior Director of Investor Relations | — |
| Dr. Elaine Carla Stracker J.D., Ph.D. | Chief Legal Officer | 1961 |
| Mr. Dave Gancarz CPA | Chief Business & Strategy Officer | — |
| Dr. Wang Clow Fong ScD | Chief Biometrics Officer | 1958 |
| Dr. Urte Gayko Ph.D. | Chief Regulatory, Quality & Pharmacovigilance Officer | 1971 |
Fundamentals
Valuation
Profitability
Trading
Source: third-party data provider, as of November 13, 2026
Technical indicators
- RSI 14
- 52.51
- MACD 12/26/9
- 0.19
- EMA 9 of MACD
- -0.03
- MACD histogram
- 0.22
- SMA 50
- $16.46
- Price above SMA 50
- EMA 50
- $15.97
- Price above EMA 50
- SMA 200
- $16.16
- Price above SMA 200
- EMA 200
- $16.42
- Price above EMA 200
Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.
Analyst views
5 analyst ratings
Third-party analyst opinion, not a recommendation from Gotrade.
- Low
- $11.90
- Average
- $24.98
- High
- $43.00
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | -2.3 | -45.1 | ||||||||||
| 2022 | -22.0 | +19.7 | -23.4 | -32.9 | -7.6 | -24.8 | +6.3 | +20.0 | -8.5 | -9.9 | -25.9 | +525.0 |
| 2023 | -29.0 | -52.6 | -3.8 | -27.9 | +9.4 | +46.8 | -13.2 | -22.5 | +14.7 | +9.6 | +4.1 | +22.5 |
| 2024 | +48.5 | +13.5 | -11.0 | -1.3 | +84.9 | -11.8 | +32.7 | +21.8 | +73.8 | -7.5 | -2.8 | -3.5 |
| 2025 | +17.2 | +3.6 | +0.8 | +28.3 | -26.1 | +20.0 | +24.4 | -12.4 | -13.3 | -7.7 | -1.8 | +1.3 |
| 2026 | -17.4 | +18.0 | +17.1 | +13.4 | +8.8 | -7.3 | -9.5 | +4.4 | +19.4 | -4.0 | +20.5 |



